Vinay Prasad US hematologist–oncologist
Prasad, Vinayak K., 1982-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Prasad, Vinayak K.
Prasad, Vinay
VIAF ID: 1147423065544881740 (Personal)
Permalink: http://viaf.org/viaf/1147423065544881740
Preferred Forms
-
100 1 _ ‡a Prasad, Vinay
-
100 1 _
‡a
Prasad, Vinayak K.
-
100 1 _
‡a
Prasad, Vinayak K.
-
100 1 _ ‡a Prasad, Vinayak K.
-
100 1 _ ‡a Prasad, Vinayak K.
-
100 1 _
‡a
Prasad, Vinayak K.
‡d
1982-
-
100 1 _
‡a
Prasad, Vinayak K.,
‡d
1982-
-
100 1 _
‡a
Prasad, Vinayak K.,
‡d
1982-
-
100 1 _ ‡a Prasad, Vinayak K., ‡d 1982-
-
100 1 _ ‡a Prasad, Vinayak K., ‡d 1982-
-
100 1 _
‡a
Prasad, Vinayak K.,
‡d
1982-....
-
100 0 _
‡a
Vinay Prasad
‡c
US hematologist–oncologist
4xx's: Alternate Name Forms (6)
Works
| Title | Sources |
|---|---|
| Eliminating chronic kidney disease... as a diagnosis |
|
| Ending medical reversal : improving outcomes, saving lives |
|
| Estimation of US patients with cancer who may respond to cytotoxic chemotherapy |
|
| Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices |
|
| The evidence landscape in precision medicine |
|
| Firearm legislation and gun-related fatalities |
|
| Freedom to Innovate: The Perils of Centralized Medical Research—Reply |
|
| The Frequency of Medical Reversal |
|
| Handheld Ultrasounds: Pocket Sized, but Pocket Ready? |
|
| Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start |
|
| The high price of anticancer drugs: origins, implications, barriers, solutions |
|
| Holiday reading: The facts are the facts |
|
| How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses |
|
| Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices |
|
| In Reply--Is There a Need for "Bias Police" in Industry-Sponsored Research? |
|
| Industry Funding of Cancer Patient Advocacy Organizations |
|
| The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy? |
|
| Innovate, reverse, repeat, 2015: |
|
| Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice? |
|
| It Is Time to Stop Screening for Prostate Cancer |
|
| Lacking the Incentive to Cure? Recurring Clostridium difficile Diarrhea and Our Reluctance to Use Fecal Transplantation |
|
| Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality |
|
| Malignant : how bad policy and bad evidence harm people with cancer |
|
| Media coverage of medical journals: do the best articles make the news? |
|
| A medical burden of proof: Towards a new ethic |
|
| Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses |
|
| A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment |
|
| The misguided ethics of crossover trials |
|
| Modern Drug Development |
|
| Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings |
|
| Multiplying therapies and reducing toxicity in metastatic melanoma |
|
| n2015180130 |
|
| New frontiers for stroke prevention in atrial fibrillation. |
|
| News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines |
|
| Non-inferiority trials: why oncologists must remain wary |
|
| Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: a good thing? |
|
| Observational studies cannot justify the inferior vena cava filter. |
|
| Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes |
|
| Open issues with open access publication |
|
| Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients |
|
| The overdiagnosis of pneumonia |
|
| The Peltzman effect and compensatory markers in medicine |
|
| Perspective: beyond storytelling in medicine: an encounter-based curriculum. |
|
| Perspective: The precision-oncology illusion |
|
| Perspective: Why There Must Be a Meditative Medicine |
|
| Politique et gestion du cancer en question : comment une politique sanitaire inadéquate et une manipulation des statistiques mettent en danger les malades du cancer |
|
| Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19 |
|
| Precision medicine in acute myeloid leukemia: Hope, hype or both? |
|
| Precision oncology: origins, optimism, and potential |
|
| Prespecified falsification end points: can they validate true observational associations? |
|
| Pricing and Value of Cancer Drugs--Reply. |
|
| Primary care physicians' role in counseling about gun safety |
|
| Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? |
|
| Publication trends among internal medicine residents and graduates |
|
| Raise the Bar Even Higher for Primary Prevention Interventions—Reply |
|
| Rebuttal from Dr Rho et al. |
|
| Reclaiming the morbidity and mortality conference: between Codman and Kundera |
|
| Regarding Empiricism and Rationalism in Medicine and 2 Medical Worldviews |
|
| Registration studies - when should patients be deemed ineligible for aggressive therapy? |
|
| The Reply |
|
| Reply to Dr. Leon: true but unrelated. |
|
| Response |
|
| The role of censoring on progression free survival: oncologist discretion advised |
|
| Rosiglitazone, medical reversal, and back to basics for diabetes |
|
| Routine Noninvasive Testing and Highly Sensitive Troponin Immunoassays—Reply |
|
| Same Data; Different Interpretations |
|
| Statins, Primary Prevention, and Overall Mortality |
|
| Steroids in infection: an old wives' tale |
|
| The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses |
|
| Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. |
|
| Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute |
|
| Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go. |
|
| Taking care of sick patients |
|
| Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies |
|
| Translation failure and medical reversal: Two sides to the same coin. |
|
| Treatment of Moderate to Severe Hidradenitis Suppurativa |
|
| The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. |
|
| US News and World Report cancer hospital rankings: do they reflect measures of research productivity? |
|
| The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival? |
|
| Vinay Prasad on the use of exaggerated language in cancer research, and how it can mislead doctors, patients, and the public |
|
| Warui ganchiryo : Ayamatta seisaku to ebidensu ga donoyoni gankanja o itametsukeruka. |
|
| Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off? |
|
| What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature |
|
| Where are randomized trials necessary: Are smoking and parachutes good counterexamples? |
|
| Why cancer screening has never been shown to "save lives"--and what we can do about it. |
|
| Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? |
|
| Why randomized controlled trials are needed to accept new practices: 2 medical worldviews |
|
| Why resident physicians stay late |
|
| The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab |
|
| প্রত্যুত্তর |
|
| 悪いがん治療 : 誤った政策とエビデンスがどのようにがん患者を痛めつけるか |
|
